Brain

PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin

PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy clinics planned for opening by…

1 year ago

IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma

First-ever orphan drug designation for genetically modified gamma-delta T cell therapiesThis orphan drug designation offers potential 7-year market exclusivity for…

1 year ago

Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment System

The FreeClimb 70 Reperfusion System, powered by the Tenzing 7 delivery catheter, enables neurointerventionalists to address critical unmet needs in…

1 year ago

Baycrest’s Goal Management Training Now Offered Through Telus Health’s AbilitiCBT Platform

First large-scale digital roll out of Baycrest’s Goal Management Training will support mental rehabilitation for people across Canada and the…

1 year ago

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability…

1 year ago

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.

Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the…

1 year ago

Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline

First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of…

1 year ago

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and…

1 year ago

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)…

1 year ago

Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain

MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) --  Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic…

1 year ago